Navigation Links
S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
Date:10/25/2011

SINGAPORE, Oct. 25, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program.

"Data from Phase 1 and 2 clinical studies have demonstrated that pacritinib is well tolerated and active in the treatment of myelofibrosis, an orphan disease with a high unmet medical need," said Tamar Howson, interim CEO and board member of S*BIO. "We are moving forward with an aggressive and focused development plan with global Phase 3 trials for pacritinib to further demonstrate its clinical benefits in MF patients and to maximise the value of our JAK2 program. We are currently in the process of identifying a suitable partner for the Phase 3 studies and pacritinib's subsequent commercialization."

The primary objective of the double-blind, placebo-controlled Phase 3 studies is to compare the efficacy of pacritinib versus placebo in achieving clinically significant reduction in spleen size in MF patients with splenomegaly. Secondary outcomes of both studies include patient-reported change in the most bothersome symptom identified at baseline, duration of response, as well as overall survival. The trials will enrol up to 500 MF patients.

In Phase 2 studies, treatment with pacritinib resulted in sustained reduction in MF-associated splenomegaly with no evidence of myelosuppression and no exacerbation of cytopenias. Pacritinib is a small molecule JAK2-selective kinase inhibitor that demonstrated high potency in preclinical models against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequency in myeloproliferative disorders such as MF. More than 50% of patients with MF possess the JAK2
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
3. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
6. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
7. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
8. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
9. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
10. CareFusion Initiates Class I Recall of EnVe Ventilators
11. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Alimera Sciences, Inc. (NASDAQ: ... the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... fiscal year 2015 financial results after the market close ... will follow on the same day at 4:30 p.m. ... and Chief Executive Officer, and Rick Eiswirth , ...
(Date:7/30/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 6, 2015, at 11:00 AM Eastern Time ... June 30, 2015, and to provide an update on ... via the Maestro® System. Conference Call Details ...
(Date:7/30/2015)... 2015 Tissue Regenix Group ... medical devices company, announces that it has further ... market as Tissue Regenix Wound Care Inc. has ... First Coast Service Options Inc. ("First Coast") whose ... Puerto Rico and the US ...
Breaking Medicine Technology:Alimera Sciences To Release Second Quarter Fiscal Year 2015 Financial Results 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3
... , , , , , , ... MIVI-TRUST Phase III Program With Microplasmin Recruits a Total of Over,640 ... (Euronext Brussels: THR), a biopharmaceutical company,focused on the discovery and development ... that it has completed,the enrolment of the second Phase III trial ...
... , NORCROSS, Ga., Dec. 15 Immucor, Inc. (Nasdaq: ... to the blood transfusion industry, today announced that it will ... 6, 2010 after the market close. The Company will host ... a.m. (Eastern Time) to discuss the results. , ...
Cached Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... at the annual All-Stars Summit. Google Partners is the platform for search marketing ... the full support and tools necessary to run successful search marketing campaigns. Google ...
(Date:7/30/2015)... ... , ... Quintessa Medical Spa is happy to offer patients the latest treatment ... for the elimination of excess tissue under the chin, referred to as submental fat. ... to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella was approved by ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American ... Chuck Rosenberg’s announcement of the reinstitution of National Prescription Drug Take-Back Days. The ... from 10:00 AM to 2:00 PM local time. On the 26th, the DEA, ...
(Date:7/30/2015)... Raleigh, NC (PRWEB) , ... July 30, 2015 , ... ... older patients. Click here to read more on the Surviving Mesothelioma website. ... Orthopedic Rehabilitation Hospital in Missouri reviewed more than 12,000 cases of mesothelioma occurring between ...
(Date:7/30/2015)... ... 30, 2015 , ... 1Heart Caregiver Services LLC is offering its 1st Business ... in the Booming Homecare Business.” This will be held in its main headquarters at ... event will be hosted by 1Heart’s very own Randy Clarito (Director of Business and ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:Upcoming Business Seminar at 1Heart Caregiver Services Headquarters Los Angeles California 2
... clinical trials, design may also mask risk of HIV drug ... new study questions whether vaginal microbicides being developed to help ... resistance from the virus that causes AIDS. , The ... Proceedings of the National Academy of Sciences , also shows ...
... anti-seizure drugs that showed double the risk , , THURSDAY, ... cause increased suicidal tendencies in patients, a U.S. health ... experts voted unanimously to back the findings on 11 ... Administration, the Associated Press reported. , In ...
... WASHINGTON, July 10 Two leading U.S. House,Judiciary Committee ... Judiciary Committee and Rep. Lamar Smith, ranking member of ... B. Mukasey to,have the Department of Justice focus its ... seeking to gain control of,U.S. copper miner ASARCO., ...
... 2008 -- Later this month, thousands of scientists and health ... the 50th meeting of the American Association of Physicists in ... July 31, they will present the latest technologies for imaging ... facing the field today. , Whether X-rays for CT ...
... of a noisy Chicago restaurant during the breakfast rush ... many voices was the crucial test of new hearing ... University School of Medicine in St. Louis. The study showed ... the most challenging test for a hearing aid. ,But ...
... Va., July 10 Axiom Resource,Management, Inc., has been ... the field of healthcare information and technology. Healthcare,Informatics magazine ... June, 2008, ranking Axiom at number 76. Axiom moved ... at number 81 on the list., Axiom managing ...
Cached Medicine News:Health News:Vaginal Microbicides Might Help More Men Than Women 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 2Health News:Epilepsy Drugs Can Cause Suicidal Tendencies, FDA Panel Finds 3Health News:Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do 'Careful Study' of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO 2Health News:Chair, Ranking Member of U.S. House Judiciary Committee Urge DOJ to do 'Careful Study' of Environmental Record of Vedanta/Sterlite, Other Would-Be Buyers of ASARCO 3Health News:Waves, particles and medicine in Houston 2Health News:New hearing aid technology passes the restaurant noise test 2Health News:New hearing aid technology passes the restaurant noise test 3
Straight shafts with 1 x 2 teeth. Flat handle with haoles and polished finish. Delicate teeth. Most popular size or model....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Manufactured in titanium....
Straight shafts with polished finish. Teeth: 0.12 mm. Tying platform: 5.0 mm. Wide Serrated....
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: